Associate Director of Non-Clinical Development, Pr
Taiwan Liposome Company
Prior to joining TLC, Dr. Hsieh worked as a reviewer and consultant in the field of Pharmacology and Toxicology at Center for Drug Evaluation (CDE) in Taiwan from 2004 to 2016, where he reviewed more than 200 IND and NDA cases including small molecule drugs and biological products and drafted several nonclinical safety guidances. As a consultant at CDE, he also provided nonclinical development strategies for local pharmaceutical companies. Dr. Hsieh received multidisciplinary training while working at CDE and is very familiar with nonclinical safety guidances. Dr. Hsieh has participated in ICH S9 and ICH E14/S7B Implementation Working Groups and served as a member of The Health Food Review Committee at Taiwan’s FDA from 2014 to 2016. Dr. Hsieh earned his Ph.D. in Pharmacology and Toxicology from the University of Mississippi Medical Center and completed his postdoctoral training at National Taiwan University and Chang Gung University.
Pharma, Clinical research, Pharmaceutical sciences